The Ongoing Debate: Longevity of Biological Valves in Pulmonary Position

Abstract

Background In patients with tetralogy of Fallot (ToF) or ToF-like anatomy, factors possibly impacting the longevity of biological valves in the pulmonary position were investigated.

Method Between 1997 and 2017, 79 consecutive hospital survivors with a median age of 8.7 years (range: 0.2–56.1 years; interquartile range [IQR]: 14.8 years) with ToF or ToF-like anatomy underwent surgical implantation of Contegra (n = 34), Hancock (n = 23), Perimount (n = 9), pulmonary homograft (n = 9), and miscellaneous (n = 4) conduits. The median internal graft diameter was 19 mm (range: 11–29 mm; IQR: 8 mm) which refers to a median z-score of 0.6 standard deviation (SD) (range: −1.8 to 4.0 SD; IQR: 2.1 SD).

Results The median time of follow-up was 9.4 years (range: 1.1–18.8 years; IQR: 6.0 years). Thirty-nine patients (49%) underwent surgical (n = 32) or interventional (n = 7) pulmonary valve re-replacement. Univariate Cox regression revealed patient age (p = 0.018), body surface area (p = 0.004), internal valve diameter (p = 0.005), and prosthesis z-score (p = 0.018) to impact valve longevity. Multivariate Cox regression analysis, however, did not show any significant effect (likely related to multicollinearity). Subgroup analysis showed that valve-revised patients have a higher average z-score (p = 0.003) and younger average age (p = 0.007).

Conclusion A decreased longevity of biological valves in the pulmonary position is related to younger age, lower valve diameter, and higher z-score. Because valve size (diameter and z-score) can be predicted by age, patient age is the crucial parameter influencing graft longevity.

Keywords

congenital heart disease - valve replacement - pulmonary valve

• References

• 1 Balzer D. Pulmonary valve replacement for tetralogy of Fallot. Methodist DeBakey Cardiovasc J 2019; 15 (02) 122-132 . Erratum in: Methodist Debakey Cardiovasc J. 2019 Jul-Sep;15(3):236. PMID: 31384375; PMCID: PMC6668735
• 2 Powell AJ, Lock JE, Keane JF, Perry SB. Prolongation of RV-PA conduit life span by percutaneous stent implantation. Intermediate-term results. Circulation 1995; 92 (11) 3282-3288
• 3 Chen PC, Sager MS, Zurakowski D. et al. Younger age and valve oversizing are predictors of structural valve deterioration after pulmonary valve replacement in patients with tetralogy of Fallot. J Thorac Cardiovasc Surg 2012; 143 (02) 352-360
• 4 Rahmath MRK, Boudjemline Y. Tetralogy of Fallot will be treated interventionally within two decades. Pediatr Cardiol 2020; 41 (03) 539-545
• 5 Jones TK, McElhinney DB, Vincent JA. et al. Long-term outcomes after melody transcatheter pulmonary valve replacement in the US investigational device exemption trial. Circ Cardiovasc Interv 2022; 15 (01) e010852
• 6 Boethig D, Avsar M, Bauer UMM. et al; National Register For Congenital Heart Defects Investigators, Evaluation of the German National Register for Congenital Heart Defects. Pulmonary valve prostheses: patient's lifetime procedure load and durability. Interact Cardiovasc Thorac Surg 2022; 34 (02) 297-306
• 7 Bapat VN, Attia R, Thomas M. Effect of valve design on the stent internal diameter of a bioprosthetic valve: a concept of true internal diameter and its implications for the valve-in-valve procedure. JACC Cardiovasc Interv 2014; 7 (02) 115-127
• 8 Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008; 21 (08) 922-934
• 9 Baird CW, Chávez M, Sleeper LA. et al. Reintervention rates after bioprosthetic pulmonary valve replacement in patients younger than 30 years of age: a multicenter analysis. J Thorac Cardiovasc Surg 2021; 161 (02) 345-362.e2
• 10 Kim DH, Kwon YK, Choi ES, Kwon BS, Park CS, Yun TJ. Risk factors for early adverse outcomes after bovine jugular vein conduit implantation: influence of oversized conduit on the outcomes. Interact Cardiovasc Thorac Surg 2022; 35 (04) ivac197
• 11 Nomoto R, Sleeper LA, Borisuk MJ. et al. Outcome and performance of bioprosthetic pulmonary valve replacement in patients with congenital heart disease. J Thorac Cardiovasc Surg 2016; 152 (05) 1333-1342.e3
• 12 Zubairi R, Malik S, Jaquiss RD, Imamura M, Gossett J, Morrow WR. Risk factors for prosthesis failure in pulmonary valve replacement. Ann Thorac Surg 2011; 91 (02) 561-565
• 13 Al Mosa AFH, Madathil S, Bernier PL, Tchervenkov C. Long-term outcome following pulmonary valve replacement in repaired tetralogy of Fallot. World J Pediatr Congenit Heart Surg 2021; 12 (05) 616-627
• 14 Sarikouch S, Koerperich H, Dubowy KO. et al; German Competence Network for Congenital Heart Defects Investigators. Impact of gender and age on cardiovascular function late after repair of tetralogy of Fallot: percentiles based on cardiac magnetic resonance. Circ Cardiovasc Imaging 2011; 4 (06) 703-711